Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche to highlight pipeline developments in London

Roche to highlight pipeline developments in London

9th December 2010

Roche is set to provide investors with the latest information on its pharmaceutical pipeline and forthcoming regulatory submissions.

In a statement published today (December 9th), the Swiss company said it expects to make up to 12 submissions for new molecular entities in key treatment areas before the end of 2013.

The firm will present an update on its pipeline activities at a research and development event for investors in London.

"Our goal is to continue delivering innovative medicines in therapeutic areas of high unmet need and to bring true medical value to patients," said Hal Barron, head of global product development and chief medical officer at Roche.

He added that "the concept of personalised healthcare" is becoming an increasingly important part of the company's development projects.

At the investor event, Roche will provide an overview of 14 new molecular entities in ongoing or planned late-stage studies.

Phase III decisions are pending on the HCV polymerase inhibitor RG7128 for hepatitis C and the asthma treatment lebrikizumab.

The firm recently published positive phase III data on Rituxan/MabThera for the treatment of asymptomatic follicular lymphoma.ADNFCR-8000103-ID-800281485-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.